Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Peripheral Artery Disease
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 40 years and 80 years
- Gender
- Both males and females
Description
A randomized, positive-control, multicenter, multiple-dose, dose-escalation phase II trial. The trial was divided into 4 dose groups: the positive drug Kaishi 10 ?g group and the alprostadil liposome for injection 40?g, 80?g, 120?g group.
A randomized, positive-control, multicenter, multiple-dose, dose-escalation phase II trial. The trial was divided into 4 dose groups: the positive drug Kaishi 10 ?g group and the alprostadil liposome for injection 40?g, 80?g, 120?g group.
Tracking Information
- NCT #
- NCT04197323
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon